Background: Breast Cancer (BC) is one of the leading malignancies affecting women worldwide. Epigenetic mechanisms regulate gene expression playing an important role in the pathophysiology of cancer. In the present study IGF2 and PTEN genes in AKT pathway were selected for evaluation.
INTRODUCTION
reast Cancer (BC) is one of the leading malignancies affecting one of nine women in their lifetime; the increasing incidence of BC in developing countries including India is alarming. India reports roughly 1, 00,000 new cases annually 1 . BC is familial or sporadic, and upto 5-10% are due to the inheritance of mutation in BRCA1 or BRCA2 2 . Earlier studies from our group did not find any association of BRCA1 mutations with sporadic BC.
BC has multifactorial causes; a complex network of relationships between genes and/or proteins, including epigenetic interactions governs the neoplastic processes. Steroid hormones have been shown to play an active role in breast epithelial cell growth, development and in lactation 3 . Since these hormones and their receptors regulate normal breast tissue, it is possible that malignant cells arising from breast tissue might also express receptors for many of these hormones and might retain some degree of hormonal dependence.
The role of epigenetics as a distinct and crucial mechanism to regulate a variety of genes (both oncogenes and tumor suppressor genes) in a tissue-specific manner has emerged as an important mechanism in cancer pathology 4 . Loss of imprinting of Insulin-like growth factor 2 (IGF2, maternally imprinted), a peptide hormone with growth promoting, mitogenic and antiapoptotic functions and its subsequent overexpression have been associated with different cancers [5] [6] [7] . Further, disrupted tumor suppressive activity by epigenetic alteration of genes like Phosphatase and tensin homolog (PTEN) leads to cell proliferation and survival via the protein kinase B pathway in the cytoplasm or faulty cell cycle arrest mechanism in the nucleus via cyclin D and pMAPK pathways.
Since evidence from previous reports pointed that hormonal factors probably played a role in the etiology of breast cancer, it was of interest to know if the above mentioned genes had direct interaction with the steroid hormones. Hence, the in silico method to evaluate the presence of steroid responsive elements in the promoter regions of IGF2 and PTEN was employed.
The drugs for the treatment of cancers are selected on the basis of their ability to interfere with specific molecules to limit the progression to cancer. The identification of appropriate drug targets depends on the detailed understanding of molecular interactions in causing cancer. The present study also focuses on understanding the interactions between the two candidate genes IGF2 and PTEN, which probably are relevant in the aetiopathogenesis of BC.
MATERIAL AND METHODS
Ninety three paired breast tissue samples (breast tumor and adjacent non-tumorous breast tissue) containing more than 70% tumor tissue, from both fresh mastectomy and archival samples were processed for methylation studies, immunohistochemistry and quantitative RT-PCR and data on the two candidate genes were obtained as described earlier 8 .
In silico method was used to evaluate the presence of steroid responsive elements in the promoter regions of IGF2 and PTEN using the MAST website, reached via the same URL as the MEME website http:// meme.sdsc. edu/ meme4_4/cgi-bin/mast.cgi.
Estrogen responsive element (ERE-5'-AGGTCANNNTGACCT-3') and progesterone responsive elements (PRE 5'-GATCTGGTACAAACTGTTCTA-3) in the promoter sequences of IGF2 (NP_000603) and PTEN (NP_000305.3) were evaluated.
RESULTS
It was found that neither ERE nor PRE were present in the promoter regions of the IGF2 and PTEN gene. Nuclear PTEN protein expression was reduced in the breast tumor tissue as compared to the adjacent normal breast tissue which was due to the reduced transcription of PTEN gene in the tumor tissue. The reduced transcript in tumor was attributed to PTEN promoter methylation in breast tumors. On the other hand, there was an increase in the IGF2 levels in breast tumor. . Expression changes in many genes and affects normal regulation of biological processes such as the cell cycle and apoptosis.
DISCUSSION

Interacting pathways
The dual function PTEN counteracts the function of many growth factors. It is a negative regulator of PI3K signaling pathway; the very pathway used by IGFs to transmit their growth stimulatory signals 10 . In the present study, normal breast tissue showed a higher expression of PTEN compared to IGF2 which was reversed in breast tumor samples. In 80-90% of breast tumors from the present work, IGF2 expression was increased and nuclear PTEN expression was seen to be decreased, suggesting that the reduced PTEN fails to negatively regulate the IGF2-AKT pathway resulting in uncontrolled cell proliferation, a hallmark of tumors (Figure 1) . PTEN is also known to regulate another cell survival pathway in the nucleus, where it is translocated from the cytoplasm and normally blocks MAPK phosphorylation, which leads to downregulation of cyclin D1, resulting in inhibition of cell cycle progression and cell proliferation 11 ( Figure 1) . A study on a mouse model indicated that IGF2 upregulates PTEN thereby, regulating the AKT pathway 12 . Reduction in nuclear PTEN observed by IHC in the present study indicates that there is a loss of check on the MAPK-cyclins resulting in unchecked cell proliferation which is observed in breast tumors.
PTEN expression is also regulated by IGF2 through a feedback loop. In breast cancers, IGF2-binding protein was found to regulate PTEN expression according to some workers 13 . The observed increase in IGF2 expression with a reduced PTEN in tumor tissue indicates failure of IGF2 to upregulate PTEN and/or PTEN degradation in the present study. That is, inspite of an increased IGF2, absence of PTEN expression could point to increased IGFBP-2 resulting in low IGF2 being available for PTEN activation. This could account for the reduction in the levels of PTEN in breast tumors studied. This may be happening in addition to the p53 downregulation of PTEN and its caspasemediated degradation. Insulin-like growth International Journal of Health and Rehabilitation Sciences Volume 1 Number 1 factor-2 (IGF-2) regulates survival genes that protect the mitochondria and promote chemoresistance 14 . IGF-2 interacts with ER-α and ER-β, and modulates their translocation to the nucleus, membrane organelles, and the mitochondria. As BC progresses to estrogenindependent growth, the insulin-like growth factor-1 receptor (IGF-1R) and the ER interact and result in enhanced activation of both receptors' signaling cascades 15 . The estrogen receptor (ER) is a primary target for breast cancer treatment. Estrogen response element (ERE) is considered to be the major regulatory element in genes regulated by estrogen receptors 16 . IGF-2 is a downstream target of prolactin signaling that lies upstream of cyclin D1 transcription and this signaling pathway is known to result in the proliferation of mammary epithelial cells 17 . Absence of the ERE and PRE on the candidate genes was also backed by recent findings of Richardson et al 14 , who suggest that IGF2 interacts with the ER-α and β via IGF-1R and modulates their translocation to the nucleus, membrane organelles and the mitochondria.
CONCLUSION
Most of the current knowledge of cancer susceptibility, progression and treatment has been generated by traditional approaches, in which small numbers of genes or proteins are characterized in depth to study the molecular mechanisms of neoplastic processes. These alterations in the oncogene and tumor suppressor gene studied, may be associated with the etiology and may be responsible for the malignant changes related to breast cancers. The current report highlights the importance and potential benefits of identifying genetic interactions at the human genome level for creating a better understanding of cancer susceptibility and progression and developing novel effective anticancer therapies.
